Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
701 to 720 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Role and Potential of Different T Helper Cell Subsets in Adoptive Cell Therapy. | Cancers (Basel) | 2023 | 36980536 | PubTator, text mining | PubMed |
| The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer-Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. | Cancers (Basel) | 2023 | 36980527 | PubTator, text mining | PubMed |
| Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype. | Biomedicines | 2023 | 36979853 | PubTator, text mining | PubMed |
| The Role of ERα and ERβ in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches. | Biomedicines | 2023 | 36979805 | PubTator, text mining | PubMed |
| Novel pathophysiological insights into CAR-T cell associated neurotoxicity. | Front Neurol | 2023 | 36970518 | PubTator, text mining | PubMed |
| Inclusion of 4-1BB Costimulation Enhances Selectivity and Functionality of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells. | Cancer Res Commun | 2023 | 36968221 | PubTator, text mining | PubMed |
| Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating. | Cancer Discov | 2023 | 36961206 | PubTator, text mining | PubMed |
| IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. | J Clin Invest | 2023 | 36951942 | PubTator, text mining | PubMed |
| Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells. | Front Immunol | 2023 | 36949949 | PubTator, text mining | PubMed |
| Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. | J Transl Med | 2023 | 36949487 | PubTator, text mining | PubMed |
| Advancing cell-based cancer immunotherapy through stem cell engineering. | Cell Stem Cell | 2023 | 36948187 | PubTator, text mining | PubMed |
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States. | Adv Ther | 2023 | 36947328 | PubTator, text mining | PubMed |
| Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR. | Mol Ther | 2023 | 36945773 | PubTator, text mining | PubMed |
| CD27 agonism coordinates with CD28 and 4-1BB signal to augment the efficacy of CAR-T cells in colorectal tumor. | Med Oncol | 2023 | 36944898 | PubTator, text mining | PubMed |
| Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. | Mol Cancer | 2023 | 36941614 | PubTator, text mining | PubMed |
| Immunotherapeutic Strategies in the Management of Osteosarcoma. | J Orthop Sports Med | 2023 | 36937115 | PubTator, text mining | PubMed |
| CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma. | Front Immunol | 2023 | 36936927 | PubTator, text mining | PubMed |
| Prognostic markers of ferroptosis-related long non-coding RNA in lung adenocarcinomas. | Front Genet | 2023 | 36923797 | PubTator, text mining | PubMed |
| Chimeric antigen receptor-T cells are effective against CEACAM5 expressing non-small cell lung cancer cells resistant to antibody-drug conjugates. | Front Oncol | 2023 | 36923424 | PubTator, text mining | PubMed |
| CD47 expression is critical for CAR T-cell survival in vivo. | J Immunother Cancer | 2023 | 36918226 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=36